Source: https://www.bankofengland.co.uk/-/media/boe/files/prudential-regulation/policy-statement/2026/january/ps126app1.pdf · captured 2026-09-29 · checked 2026-09-29 · c75b8196

Page 406 thumbnail
21578 This document is effective from 1 January 2027 to accompany PS1/26.
21579Please see: www.bankofengland.co.uk/prudential-regulation/publication/2026/january/implementation-of-basel-3-1-final-rules-policy-statement.
21580 PRA2026/1
21582 (b) all documentation used in collateralised transactions is binding on all parties and
21583 legally enforceable in all relevant jurisdictions; and
21585 (c) the firm has conducted sufficient legal review to verify the condition in point (b) of
21586 5.9(2) and undertakes such further review as necessary to ensure continuing
21587 enforceability.
21589 (3) a firm must, for exposures to counterparties subject to a margin agreement, ensure that:
21591 (a) the simulated paths of discounted future exposure capture the effects of margining
21592 collateral that is recognised as risk mitigation along each exposure path;
21594 (b) its exposure model appropriately captures all the relevant contractual features
21595 including whether unilateral or bilateral, the frequency of margin calls, the type of
21596 collateral, margin thresholds, independent amounts, initial margins and minimum
21597 transfer amounts; and
21599 (c) its exposure model assumes a margin period of risk which cannot be less than:
21601 (i) 4+N business days for securities financing transactions unless the margin
21602 agreement has daily or intra-daily exchange of margin, where the margin period
21603 of risk is 5 business days; or
21605 (ii) 9+N business days for all other transactions;
21607 where:
21609 N = the re-margining period specified in the margin agreement.
21611 5.10 A firm must:
21612 (1) obtain the simulated paths of discounted future exposure from the exposure models used
21613 by the firm for calculating CVA under the firm’s applicable accounting framework, adjusted
21614 as necessary to meet the requirements of this Chapter; and
21616 (2) use the same model calibration process (with the exception of the margin period of risk),
21617 market and transaction data as it uses for calculating CVA under the firm’s applicable
21618 accounting framework.
21620 5.11 A firm must ensure the generation of market risk factor paths underlying its exposure models
21621 comply with the following requirements:
21622 (1) drifts of risk factors are consistent with a risk-neutral probability measure and not historical
21623 calibration of drifts;
21625 (2) the volatilities and correlations of risk factors are calibrated to:
21627 (a) market data, if sufficient data exist in a given market; or
21629 (b) historical market data, if sufficient data is not available; and
21631 (3) the distribution of modelled risk factors account for the possible non-normality of the
21632 distribution of exposures.
21634 5.12 A firm must ensure that its calculation of regulatory CVA recognises netting sets in the same
21635 manner in which the firm calculates CVA under the firm’s applicable accounting framework.
21636 Qualitative requirements
21638 Page 406 of 492